Abstract:Background: Protein arginine methyltransferase 5 (PRMT5) is a type II arginine methyltransferase that symmetrically di-methylates arginine residues on both histone and non-histone protein substrates. Accumulating evidence suggests that PRMT5 exerts its oncogenic properties in a wide spectrum of human malignancies. However, the underlying mechanisms by which PRMT5 contributes to the progression of colorectal cancer (CRC) remain to be defined.Methods: Western blot and real-time PCR were used to analyze the expression of CDKN2B. Co-immunoprecipitation (Co-IP), immunofluorescence and GST pulldown assays were employed to investigate the interaction between PRMT5 and EZH2. Luciferase reporter and chromatin immunoprecipitation (ChIP) assays were performed to validate CDKN2B as a direct target of PRMT5/EZH2. DNA methylation status at the CpG islands of promoter region of CDKN2B gene was analyzed by bisulfite sequencing. The effect of PRMT5/EZH2 on malignant phenotypes was examined through in vitro and in vivo assays. PRMT5 and EZH2 protein expression levels in CRC tissues were analyzed by immunohistochemistry (IHC) staining.Results: We observed that PRMT5-deficient CRC cells exhibit proliferation defects in vitro. PRMT5 was identified as a major transcriptional repressor of CDKN2B (p15INK4b) for determining CRC progression. Mechanistically, PRMT5-mediated histone marks H4R3me2s and H3R8me2s were predominantly deposited at the promoter region of CDKN2B gene in CRC cells. Knockdown of PRMT5 in CRC cells decreased the accumulation of H4R3me2s and H3R8me2s marks and reduced the CpG methylation level of CDKN2B promoter, then re-activated CDKN2B expression. Strikingly, silencing of CDKN2B partially abrogated the proliferation defects caused by PRMT5 depletion in vitro and in vivo. Furthermore, we proved that PRMT5 interacted with Enhancer of zeste homolog 2 (EZH2), leading to enhanced EZH2 binding and H3K27me3 deposition together with decreased transcriptional output of CDKN2B gene. Importantly, we found that the combined interventions exerted a synergistic inhibitory effect of combined treatment with PRMT5i (GSK591) and EZH2i (GSK126) on the growth of CRC cells/xenografts in vitro and in vivo. Moreover, PRMT5 and EZH2 were found to be significantly elevated and associated with poor prognosis in CRC patients.Conclusion: PRMT5 functionally associates with EZH2 to promote CRC progression through epigenetically repressing CDKN2B expression. Thus, our findings raise the possibility that combinational intervention of PRMT5 and EZH2 may be a promising strategy for CRC therapy.

Ros-Mediated Hypomethylation Of Prdx5 Promotes Stat3 Binding And Activates The Nrf2 Signaling Pathway In Nsclc

PRDX5 As a Novel Binding Partner in Nrf2-mediated NSCLC Progression under Oxidative Stress.

Cullin-5 Neddylation-Mediated NOXA Degradation is Enhanced by PRDX1 Oligomers in Colorectal Cancer

Promoter Methylation-Mediated Downregulation of PRDM5 Contributes to the Development of Lung Squamous Cell Carcinoma.

The Epigenetic Modifier PRDM5 Functions As a Tumor Suppressor Through Modulating WNT/β-catenin Signaling and is Frequently Silenced in Multiple Tumors.

PRMT5 Enables Robust STAT3 Activation via Arginine Symmetric Dimethylation of SMAD7

Silencing of PRDX2 Inhibits the Proliferation and Invasion of Non-Small Cell Lung Cancer Cells

Hypoxic‐stabilized EPAS1 Proteins Transactivate DNMT1 and Cause Promoter Hypermethylation and Transcription Inhibition of EPAS1 in Non‐small Cell Lung Cancer

Nucleophosmin Regulates Intracellular Oxidative Stress Homeostasis via Antioxidant PRDX6

Deregulation of PRDM5 promotes cell proliferation by regulating JAK/STAT signaling pathway through SOCS1 in human lung adenocarcinoma

Peroxiredoxin 1 regulates crosstalk between pyroptosis and autophagy in oral squamous cell carcinoma leading to a potential pro-survival

Epigenetic Silencing of PRSS3 Provides Growth and Metastasis Advantage for Human Hepatocellular Carcinoma

Comprehensive Analysis of the PRDXs Family in Head and Neck Squamous Cell Carcinoma

PRMT5 functionally associates with EZH2 to promote colorectal cancer progression through epigenetically repressing CDKN2B expression

PSMD12 promotes non-small cell lung cancer progression through activating the Nrf2/TrxR1 pathway

Critical Role of Delta Dnmt3b4/2 in Regulating Rassf1a Promoter-Specific Dna Methylation in Non-Small Cell Lung Cancer

Methylation of PRDM2, PRDM5 and PRDM16 Genes in Lung Cancer Cells.

Prognostic Significance of STAT3 Expression and Its Correlation with Chemoresistance of Non-Small Cell Lung Cancer Cells

The synergistic effects of PRDX5 and Nrf2 on lung cancer progression and drug resistance under oxidative stress in the zebrafish models

Glutaredoxin 3 promotes migration and invasion via the Notch signalling pathway in oral squamous cell carcinoma

Frequent epigenetic suppression of tumor suppressor gene glutathione peroxidase 3 by promoter hypermethylation and its clinical implication in clear cell renal cell carcinoma.